1-20 of 55
Jose Baselga
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Editor’s Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis

Federico Rojo, Laura Najera, José Lirola, José Jiménez, Marta Guzmán, M. Dolors Sabadell, Jose Baselga, Santiago Ramon y Cajal
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (16): 3641.
https://doi.org/10.1158/1078-0432.CCR-24-2176
Published: 15 August 2024
View article titled, Editor’s Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis
Open the PDF for Editor’s Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis in another window
Journal Articles

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3947–3957.
https://doi.org/10.1158/1078-0432.CCR-19-3953
Published: 03 August 2020
View article titled, Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Open the PDF for Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial

Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Paola Tiberio, Marilena V. Iorio, Florentine Hilbers, Evandro de Azambuja, Lorena de la Peña, Miguel Izquierdo, Jens Huober, José Baselga, Martine Piccart, Filippo G. de Braud, Giovanni Apolone, Paolo Verderio, Maria Grazia Daidone
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (13): 3887–3895.
https://doi.org/10.1158/1078-0432.CCR-18-2507
Published: 01 July 2019
View article titled, Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Open the PDF for Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

Françoise Rothé, Maria Joao Silva, David Venet, Christine Campbell, Ian Bradburry, Ghizlane Rouas, Evandro de Azambuja, Marion Maetens, Debora Fumagalli, Vanessa Rodrik-Outmezguine, Serena Di Cosimo, Daniela Rosa, Stephen Chia, Andrew Wardley, Takayuki Ueno, Wolfgang Janni, Jens Huober, Jose Baselga, Martine Piccart, Sherene Loi, Christos Sotiriou, Sarah-Jane Dawson, Michail Ignatiadis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3581–3588.
https://doi.org/10.1158/1078-0432.CCR-18-2521
Published: 14 June 2019
View article titled, Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Open the PDF for Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric-Bernstam, Josep Tabernero, Filip Janku, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, Yulia Kirpicheva, Valerie Nicolas-Metral, Anna Pokorska-Bocci, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, Jose Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (9): 2699–2707.
https://doi.org/10.1158/1078-0432.CCR-18-1959
Published: 01 May 2019
View article titled, A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <em>FGFR</em> Gene Alterations
Open the PDF for A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <em>FGFR</em> Gene Alterations in another window
Includes: Supplementary data
Journal Articles

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1434.
https://doi.org/10.1158/1078-0432.CCR-18-4267
Published: 15 February 2019
View article titled, Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Journal Articles

Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials

Yingbing Wang, Karen L. Ayres, Debra A. Goldman, Maura N. Dickler, Aditya Bardia, Ingrid A. Mayer, Eric Winer, Jill Fredrickson, Carlos L. Arteaga, José Baselga, Henry C. Manning, Umar Mahmood, Gary A. Ulaner
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1435.
https://doi.org/10.1158/1078-0432.CCR-18-4266
Published: 15 February 2019
View article titled, Correction: <sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
Open the PDF for Correction: <sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials in another window
Journal Articles

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Maura N. Dickler, Cristina Saura, Donald A. Richards, Ian E. Krop, Andrés Cervantes, Philippe L. Bedard, Manish R. Patel, Lajos Pusztai, Mafalda Oliveira, Alison K. Cardenas, Na Cui, Timothy R. Wilson, Thomas J. Stout, Michael C. Wei, Jerry Y. Hsu, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4380–4387.
https://doi.org/10.1158/1078-0432.CCR-18-0613
Published: 14 September 2018
View article titled, Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
Open the PDF for Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Diéras, Debra Patt, Hans Wildiers, Clifford A. Hudis, Joyce O'Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5218–5224.
https://doi.org/10.1158/1078-0432.CCR-17-0754
Published: 31 August 2017
View article titled, MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer
Open the PDF for MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4323–4334.
https://doi.org/10.1158/1078-0432.CCR-16-2287
Published: 01 August 2017
View article titled, HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Includes: Supplementary data
Journal Articles

18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials

Yingbing Wang, Karen L. Ayres, Debra A. Goldman, Maura N. Dickler, Aditya Bardia, Ingrid A. Mayer, Eric Winer, Jill Fredrickson, Carlos L. Arteaga, José Baselga, Henry C. Manning, Umar Mahmood, Gary A. Ulaner
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3053–3060.
https://doi.org/10.1158/1078-0432.CCR-16-2197
Published: 14 June 2017
View article titled, <sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
Open the PDF for <sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials in another window
Journal Articles

Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors

Adriana Soler, Ana M. Figueiredo, Pau Castel, Laura Martin, Erika Monelli, Ana Angulo-Urarte, Maria Milà-Guasch, Francesc Viñals, Jose Baselga, Oriol Casanovas, Mariona Graupera
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5805–5817.
https://doi.org/10.1158/1078-0432.CCR-15-3051
Published: 30 November 2016
View article titled, Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Open the PDF for Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers

Violeta Serra, Cristina Cruz, Marta Castroviejo, Sara Gutiérrez, Alba Llop, Alejandra Bruna, Beatriz Morancho, Ginevra Caratú, Ludmila Prudkin, Ana Vivancos, Paolo Nuciforo, Mark O'Connor, Jos Jonkers, Carlos Caldas, Joaquin Arribas, José Baselga, Isabel T. Rubio, Cristina Saura, Orland Díez, Judith Balmaña, Javier Cortés
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): B02.
https://doi.org/10.1158/1557-3265.PDX16-B02
Published: 15 August 2016
View article titled, Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers
Journal Articles

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna K. Samant, Steve Olsen, Sanne L. de Haas, Mark D. Pegram
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (15): 3755–3763.
https://doi.org/10.1158/1078-0432.CCR-15-2499
Published: 31 July 2016
View article titled, Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Open the PDF for Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors

Eneda Toska, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2099–2101.
https://doi.org/10.1158/1078-0432.CCR-16-0038
Published: 01 May 2016
View article titled, Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors
Open the PDF for Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors in another window
Journal Articles

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

Zachary S. Zumsteg, Natasha Morse, Gabriel Krigsfeld, Gaorav Gupta, Daniel S. Higginson, Nancy Y. Lee, Luc Morris, Ian Ganly, Stephan L. Shiao, Simon N. Powell, Christine H. Chung, Maurizio Scaltriti, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (8): 2009–2019.
https://doi.org/10.1158/1078-0432.CCR-15-2245
Published: 14 April 2016
View article titled, Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating <em>PIK3CA</em> Alterations
Open the PDF for Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating <em>PIK3CA</em> Alterations in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy

Maurizio Scaltriti, Moshe Elkabets, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1313–1317.
https://doi.org/10.1158/1078-0432.CCR-15-1458
Published: 14 March 2016
View article titled, Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Open the PDF for Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy in another window
Journal Articles

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

Celina García-García, Martín A. Rivas, Yasir H. Ibrahim, María Teresa Calvo, Albert Gris-Oliver, Olga Rodríguez, Judit Grueso, Pilar Antón, Marta Guzmán, Claudia Aura, Paolo Nuciforo, Katti Jessen, Guillem Argilés, Rodrigo Dienstmann, Andrea Bertotti, Livio Trusolino, Judit Matito, Ana Vivancos, Irene Chicote, Héctor G. Palmer, Josep Tabernero, Maurizio Scaltriti, José Baselga, Violeta Serra
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (24): 5499–5510.
https://doi.org/10.1158/1078-0432.CCR-14-3091
Published: 14 December 2015
View article titled, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <em>TP53</em> Mutation in Preclinical Models of Colorectal Cancer
Open the PDF for MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <em>TP53</em> Mutation in Preclinical Models of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

AACR Cancer Progress Report 2015

José Baselga, Nina Bhardwaj, Lewis C. Cantley, Ronald DeMatteo, Raymond N. DuBois, Margaret Foti, Susan M. Gapstur, William C. Hahn, Lee J. Helman, Roy A. Jensen, Electra D. Paskett, Theodore S. Lawrence, Stuart G. Lutzker, Eva Szabo
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19_Supplement): S1–S128.
https://doi.org/10.1158/1078-0432.CCR-15-1846
Published: 30 September 2015
View article titled, AACR Cancer Progress Report 2015
Open the PDF for AACR Cancer Progress Report 2015 in another window
Includes: Supplementary data
Journal Articles

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Dejan Juric, Rodrigo Dienstmann, Andres Cervantes, Manuel Hidalgo, Wells Messersmith, George R. Blumenschein, Jr, Josep Tabernero, Desamparados Roda, Antonio Calles, Antonio Jimeno, Xiaodong Wang, Sandra Sanabria Bohórquez, Cecilia Leddy, Catherine Littman, Amy V. Kapp, David S. Shames, Elicia Penuel, Lukas C. Amler, Andrea Pirzkall, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2462–2470.
https://doi.org/10.1158/1078-0432.CCR-14-2412
Published: 31 May 2015
View article titled, Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
Open the PDF for Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors in another window